ProCE Banner Activity

Acute Myeloid Leukemia: Will Understanding the Biology Lead to Better Outcomes?

Clinical Thought
New therapeutic targets are beginning to offer improved strategies for AML treatment.

Released: March 26, 2015

Expiration: March 24, 2016

No longer available for credit.

Share

Faculty

Farhad Ravandi

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Novartis Oncology

Faculty Disclosure

Primary Author

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Farhad Ravandi, MD, has disclosed that he has received consulting fees from Amgen, Incyte, Karyopharm, Pfizer, and Sunesis and funds for research support from Amgen, Bristol-Myers Squibb, Incyte, Seattle Genetics, and Sunesis.